Grace Therapeutics Details Path Forward for GTx-104 After FDA CRL, Highlights Positive Phase 3 Safety Data
GRCE sits 26% above its 52-week low of $1.79 on light trading volume (0.2× avg).
Summary
Grace Therapeutics updated its corporate presentation, detailing the path to resubmission for its lead drug GTx-104 after an FDA Complete Response Letter and highlighting positive Phase 3 safety trial observations.
Key Events · Product Development and Regulatory · GRCE
-
FDA CRL Clarification
The Complete Response Letter for GTx-104 was attributed to Chemistry, Manufacturing, and Controls (CMC) and manufacturing readiness issues, with no clinical deficiencies identified.
-
Type A Meeting Scheduled
A Type A meeting with the FDA is scheduled to clarify the path for GTx-104 resubmission, following the recent CRL.
-
Positive Phase 3 Safety Data
The STRIVE-ON Phase 3 safety trial showed GTx-104 led to ~19% fewer patients with clinically significant hypotension, 54% higher relative dose intensity, and a ~29% relative increase in good recovery at 90 days compared to oral nimodipine. (Note: Trial was not statistically powered for hypothesis testing of efficacy).
-
Pharmacoeconomic Benefits Observed
Trial observations indicated 1.5 fewer ICU days, 5 fewer ventilator days, and 48% fewer ICU readmissions with GTx-104 compared to oral nimodipine.
Analysis · GRCE · Life Sciences
This 8-K updates the corporate presentation, providing critical details on Grace Therapeutics' strategy following the FDA's Complete Response Letter (CRL) for its lead drug candidate, GTx-104. The presentation clarifies that the CRL was due to Chemistry, Manufacturing, and Controls (CMC) and manufacturing readiness issues, not clinical deficiencies. It also highlights positive observations from the Phase 3 STRIVE-ON safety trial, showing potential benefits in reducing hypotension, improving patient recovery, and decreasing ICU/ventilator days compared to oral nimodipine. This update is crucial for investors, especially given the company's recent 10-K filing which raised going concern doubts, as it outlines the company's plan to address regulatory hurdles and leverage its clinical data to advance GTx-104.
At the time of this filing, GRCE was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.4M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.